Developer docs
API playgroundTry for free, no card

Search company profiles

Phyton Biotech

Full company profile

uuid000akpb

Namestring
Phyton Biotech
Legal namestring
Phyton Biotech GmbH
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFort Worth, United States
HQ citystring
Fort Worth
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
plant cell fermentation, pharmaceutical API manufacturing, CDMO services, biotech contract manufacturing, natural product fermentation
Industry3 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Active Pharmaceutical Ingredients (API) Sales
TypeOne Time License
Description

Production and sale of API-grade paclitaxel and docetaxel as the world's largest supplier of these products via PCF technology. Revenue generated from product sales to pharmaceutical manufacturers.

phytonbiotech.com
2Contract Manufacturing Services
TypeProfessional Services
Description

Full range of integrated contract product and process development and commercial manufacturing services across the entire development chain, from feasibility to commercial production. Includes specialty fermentation and commercial downstream processing.

phytonbiotech.com
3Reference Standards
TypeTransaction Fee
Description

Sale of reference standard products including paclitaxel, docetaxel, and related compounds for laboratory use. Products sold in 10mg packaging with prepaid payment terms.

phytonbiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1API products (Paclitaxel, Docetaxel) - custom quotation based
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for bulk API purchases; no public price list available

phytonbiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Phyton Biotech is a contract development and manufacturing organization (CDMO) that produces pharmaceutical active ingredients (APIs) using proprietary plant cell fermentation (PCF®) technology. Its portfolio includes the anti-cancer APIs Paclitaxel and Docetaxel, the QS-21 vaccine adjuvant, reference standards, and custom fermentation/downstream processing services for clients developing complex plant-derived compounds such as the antibiotic Corallopyronin A. The company serves pharmaceutical, biotech, and research organizations requiring sustainable, scalable, and GMP-compliant supply of high-value botanical APIs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80-92% reduction in solvent usage compared to traditional paclitaxel manufacturing processes
+3 more records
Product overview1 text field

Phyton Biotech is a specialty fermentation company operating the world's largest plant cell fermentation (PCF®) facility, serving as a CDMO (Contract Development and Manufacturing Organization) for the pharmaceutical and related industries. The core offering is the proprietary PCF® technology platform for sustainable production of high-value phytochemicals. The product portfolio centers on two flagship APIs—Paclitaxel and Docetaxel—produced via plant cell fermentation, making Phyton the world's largest supplier of these cancer drugs. Additional offerings include specialty fermentation contract services (from feasibility through commercial production), commercial downstream processing, and an extensive catalog of over 30 reference standards for taxane compounds. Recent developments include Corallopyronin A (anti-infective) technology transfer and QS-21 vaccine adjuvant production via plant cell culture. The company operates GMP-certified facilities in Germany and Canada with over 200 m³ of installed fermentation capacity.

Product and service1 record
1Paclitaxel API
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Collaboration in Corallopyronin A development for neglected tropical diseases. UKB leads the broader clinical development program for this novel anti-infective agent targeting filarial infections such as river blindness and lymphatic filariasis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Partner in Corallopyronin A development consortium; developed the optimized heterologous production strain of Myxococcus xanthus for CorA manufacturing under Prof. Rolf Müller's leadership.

3German Center for Infection Research (DZIF)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Supports the broader clinical development program for Corallopyronin A as a new treatment for diseases disproportionately affecting underserved populations. Key coordinator of international collaboration.

phytonbiotech.com
4Eisai Co. Ltd.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Collaboration through GHIT Fund for advancing Corallopyronin A as a treatment option for neglected tropical diseases in collaboration with academic institutions.

phytonbiotech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-11
Description

Successfully established high-yielding plant cell lines of cyclopamine source for PellePharm's patedigib topical gel targeting rare dermatologic conditions using PCF technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty ingredients and fermentation-derived nutraceutical/pharmaceutical ingredient producer with large-scale fermentation assets. Comparable to Phyton in the use of industrial fermentation for high-value ingredients, though DSM operates across a much broader specialty ingredients portfolio.

TypeBroad incumbent
Description

Global CDMO services including API manufacturing, biologics, and sterile fill-finish across hundreds of programs. Comparable to Phyton as a diversified contract manufacturer serving pharma, with substantially larger scale and scope.

TypeBroad incumbent
Description

Global CDMO leader with large-scale microbial and mammalian fermentation capacity for APIs and biologics. Comparable to Phyton as a contract manufacturer of complex pharmaceutical inputs at industrial scale, though Lonza operates across a much broader portfolio than Phyton's plant-cell-fermentation niche.

TypeBroad incumbent
Description

Global CDMO providing development and manufacturing for small molecules and biologics, including fermentation-based services. Comparable to Phyton as a contract API/biological manufacturer serving pharma, with substantially broader service breadth.

TypeDirect peer
Description

Contract development and manufacturing organization offering process development, clinical and commercial manufacturing for small molecules and biologics. Comparable to Phyton as a fermentation-capable CDMO serving pharma, with a more discovery-led service model.

TypeBroad incumbent
Description

Major biologics CDMO with extensive microbial and mammalian fermentation capacity. Comparable to Phyton as a global GMP contract manufacturer for complex therapeutics, though WuXi operates at significantly larger scale and primarily in mammalian systems.

TypeDirect peer
Description

CDMO specializing in microbial fermentation, complex small molecules, and biologics manufacturing for pharmaceutical clients. Closely comparable to Phyton as a fermentation-focused CDMO with cGMP capacity and a focus on high-value APIs.

TypeEmerging player
Description

US-based plant cell fermentation company developing bioactive ingredients for cosmetics, food, and supplements using proprietary plant cell culture technology. Directly comparable to Phyton in using plant cell fermentation for high-value ingredients, though at an earlier commercial stage and in different end-markets.

TypeDirect peer
Description

CDMO offering microbial and mammalian cell-based biopharmaceutical manufacturing including recombinant proteins and APIs. Comparable to Phyton as a mid-sized, multi-site GMP contract manufacturer with fermentation expertise and a focus on complex molecules.

TypeBroad incumbent
Description

Large-scale biologics CDMO with multi-site GMP manufacturing for monoclonal antibodies and recombinant proteins. Comparable to Phyton as a high-capacity GMP contract manufacturer serving global pharma, though Samsung focuses on mammalian biologics rather than plant-cell fermentation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phyton Biotech

Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO)phytonbiotech.com

Phyton Biotech firmographics

Firmographics
Name
Phyton Biotech
Legal name
Phyton Biotech GmbH
Website
https://phytonbiotech.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Phyton Biotech industry classification

Industry
Product category
Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Plant cell fermentation
  • Pharmaceutical API manufacturing
  • CDMO services
  • Biotech contract manufacturing
  • Natural product fermentation

Where Phyton Biotech is headquartered

Location

Headquarters

HQ city
Fort Worth
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Phyton Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Active Pharmaceutical Ingredients (API) Sales: Production and sale of API-grade paclitaxel and docetaxel as the world's largest supplier of these products via PCF technology. Revenue generated from product sales to pharmaceutical manufacturers.
  2. Contract Manufacturing Services: Full range of integrated contract product and process development and commercial manufacturing services across the entire development chain, from feasibility to commercial production. Includes specialty fermentation and commercial downstream processing.
  3. Reference Standards: Sale of reference standard products including paclitaxel, docetaxel, and related compounds for laboratory use. Products sold in 10mg packaging with prepaid payment terms.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractAPI products (Paclitaxel, Docetaxel) - custom quotation based

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Phyton Biotech product offering

Product offering

Core offering

Phyton Biotech is a contract development and manufacturing organization (CDMO) that produces pharmaceutical active ingredients (APIs) using proprietary plant cell fermentation (PCF®) technology. Its portfolio includes the anti-cancer APIs Paclitaxel and Docetaxel, the QS-21 vaccine adjuvant, reference standards, and custom fermentation/downstream processing services for clients developing complex plant-derived compounds such as the antibiotic Corallopyronin A. The company serves pharmaceutical, biotech, and research organizations requiring sustainable, scalable, and GMP-compliant supply of high-value botanical APIs.

Product overview

Phyton Biotech is a specialty fermentation company operating the world's largest plant cell fermentation (PCF®) facility, serving as a CDMO (Contract Development and Manufacturing Organization) for the pharmaceutical and related industries. The core offering is the proprietary PCF® technology platform for sustainable production of high-value phytochemicals. The product portfolio centers on two flagship APIs—Paclitaxel and Docetaxel—produced via plant cell fermentation, making Phyton the world's largest supplier of these cancer drugs. Additional offerings include specialty fermentation contract services (from feasibility through commercial production), commercial downstream processing, and an extensive catalog of over 30 reference standards for taxane compounds. Recent developments include Corallopyronin A (anti-infective) technology transfer and QS-21 vaccine adjuvant production via plant cell culture. The company operates GMP-certified facilities in Germany and Canada with over 200 m³ of installed fermentation capacity.

Differentiator

Problem solved

Functional benefit

Products and services

  • Paclitaxel API

Quantifiable outcome

  • 80-92% reduction in solvent usage compared to traditional paclitaxel manufacturing processes
  • +3 more outcomes

Companies that use Phyton Biotech

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles2 records

Phyton Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Phyton Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • University Hospital Bonn (UKB)coreStrategic or Co-development Partner · 2 February 2026Collaboration in Corallopyronin A development for neglected tropical diseases. UKB leads the broader clinical development program for this novel anti-infective agent targeting filarial infections such as river blindness and lymphatic filariasis.
  • Helmholtz Centre for Infection Research (HZI)coreStrategic or Co-development Partner · 2 February 2026Partner in Corallopyronin A development consortium; developed the optimized heterologous production strain of Myxococcus xanthus for CorA manufacturing under Prof. Rolf Müller's leadership.
  • German Center for Infection Research (DZIF)coreStrategic or Co-development Partner · 2 February 2026Supports the broader clinical development program for Corallopyronin A as a new treatment for diseases disproportionately affecting underserved populations. Key coordinator of international collaboration.
  • Eisai Co. Ltd.minorStrategic or Co-development Partner · 2 February 2026Collaboration through GHIT Fund for advancing Corallopyronin A as a treatment option for neglected tropical diseases in collaboration with academic institutions.
  • PellePharmminorStrategic or Co-development Partner · 11 January 2021Successfully established high-yielding plant cell lines of cyclopamine source for PellePharm's patedigib topical gel targeting rare dermatologic conditions using PCF technology.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Phyton Biotech competitors and assessment

Company assessment

Broad incumbents

  • DSM-Firmenich (Animal Nutrition & Health / i-Health): Specialty ingredients and fermentation-derived nutraceutical/pharmaceutical ingredient producer with large-scale fermentation assets. Comparable to Phyton in the use of industrial fermentation for high-value ingredients, though DSM operates across a much broader specialty ingredients portfolio.
  • Thermo Fisher Scientific (Patheon CDMO): Global CDMO services including API manufacturing, biologics, and sterile fill-finish across hundreds of programs. Comparable to Phyton as a diversified contract manufacturer serving pharma, with substantially larger scale and scope.
  • Lonza Group: Global CDMO leader with large-scale microbial and mammalian fermentation capacity for APIs and biologics. Comparable to Phyton as a contract manufacturer of complex pharmaceutical inputs at industrial scale, though Lonza operates across a much broader portfolio than Phyton's plant-cell-fermentation niche.
  • Catalent: Global CDMO providing development and manufacturing for small molecules and biologics, including fermentation-based services. Comparable to Phyton as a contract API/biological manufacturer serving pharma, with substantially broader service breadth.
  • WuXi Biologics: Major biologics CDMO with extensive microbial and mammalian fermentation capacity. Comparable to Phyton as a global GMP contract manufacturer for complex therapeutics, though WuXi operates at significantly larger scale and primarily in mammalian systems.
  • Samsung Biologics: Large-scale biologics CDMO with multi-site GMP manufacturing for monoclonal antibodies and recombinant proteins. Comparable to Phyton as a high-capacity GMP contract manufacturer serving global pharma, though Samsung focuses on mammalian biologics rather than plant-cell fermentation.

Direct peers

  • Evotec: Contract development and manufacturing organization offering process development, clinical and commercial manufacturing for small molecules and biologics. Comparable to Phyton as a fermentation-capable CDMO serving pharma, with a more discovery-led service model.
  • BioVectra: CDMO specializing in microbial fermentation, complex small molecules, and biologics manufacturing for pharmaceutical clients. Closely comparable to Phyton as a fermentation-focused CDMO with cGMP capacity and a focus on high-value APIs.
  • AGC Biologics: CDMO offering microbial and mammalian cell-based biopharmaceutical manufacturing including recombinant proteins and APIs. Comparable to Phyton as a mid-sized, multi-site GMP contract manufacturer with fermentation expertise and a focus on complex molecules.

Emerging players

  • Ayana Bio: US-based plant cell fermentation company developing bioactive ingredients for cosmetics, food, and supplements using proprietary plant cell culture technology. Directly comparable to Phyton in using plant cell fermentation for high-value ingredients, though at an earlier commercial stage and in different end-markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Phyton Biotech social profiles

Digital presence

Phyton Biotech compliance and trust

Trust signal

Compliance12 records

Phyton Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phyton Biotech leadership team

Management profile

Number of profiles

Profiles4 records

Phyton Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phyton Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phyton Biotech

What does Phyton Biotech do?

Phyton Biotech is a contract development and manufacturing organization (CDMO) that produces pharmaceutical active ingredients (APIs) using proprietary plant cell fermentation (PCF®) technology. Its portfolio includes the anti-cancer APIs Paclitaxel and Docetaxel, the QS-21 vaccine adjuvant, reference standards, and custom fermentation/downstream processing services for clients developing complex plant-derived compounds such as the antibiotic Corallopyronin A. The company serves pharmaceutical, biotech, and research organizations requiring sustainable, scalable, and GMP-compliant supply of high-value botanical APIs.

Is Phyton Biotech a public or private company?

Phyton Biotech is a private company. It is classified as unknown and is currently operating.

When was Phyton Biotech founded?

Phyton Biotech was founded in 2009. It employs 101 to 250 people.

Where is Phyton Biotech based?

Phyton Biotech is headquartered in Fort Worth, United States, in the North America region.

How does Phyton Biotech make money?

Three revenue lines are on record. Active Pharmaceutical Ingredients (API) Sales are the primary driver. The others are contract Manufacturing Services and reference Standards.

Who are Phyton Biotech's main competitors?

Broad incumbents on record are DSM-Firmenich (Animal Nutrition & Health / i-Health), Thermo Fisher Scientific (Patheon CDMO), Lonza Group, Catalent, WuXi Biologics and Samsung Biologics. Direct peers are Evotec, BioVectra and AGC Biologics. Ayana Bio is listed as an emerging player.

Does Phyton Biotech have an API?

No public API is recorded for Phyton Biotech.

What industry is Phyton Biotech in?

Phyton Biotech's product category is Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AgFunderNewsFrom Taxol to cocoa: Can plant cell culture make the leap from drugs to food?Multiple plant cell culture startups are attempting to apply bioreactor technology—historically used for pharmaceuticals like Taxol—to produce high-value food ingredients such as cocoa, saffron, vanilla, and botanicals, as climate shocks and geopolitical instability threaten traditional agricultural supply chains. Key challenges remain prohibitive capital costs for bioreactors, complex regulatory pathways that lack harmonization between the US and EU, and the need to achieve cost parity with conventional agriculture while securing sufficient funding in a capital-constrained environment. Notable players include Phyton Biotech (which operates the world's largest plant cell fermentation facility), California Cultured (which just completed its first 2,000-L production run), Food Brewer (scaling cocoa), and Ayana Bio (developing sage, saffron, and marigold ingredients), with several firms targeting commercial launches by year-end pending FDA GRAS approvals.PR NewswireAgenus Awarded Grant to Enable QS-21 InnovationsAgenus Inc. received a grant of approximately $1 million from the Bill & Melinda Gates Foundation to develop an alternative plant cell culture-based manufacturing process for its proprietary QS-21 Stimulon® adjuvant, currently sourced from Chilean soap bark trees. The project will be executed in partnership with Phyton Biotech, which will utilize its Plant Cell Fermentation technology to demonstrate feasible large-scale production of the adjuvant. QS-21 is a critical component in multiple vaccines including GSK's Shingrix® and Mosquirix, as well as Agenus's own cancer vaccines.PR NewswireUne demande de brevet concernant une nouvelle méthode de production du mébutate d'ingénol chez Phyton Biotech est publiée par l'Organisation mondiale de la propriété intellectuelle (OMPI)Phyton Biotech announced that its international patent application PCT/EP2016/055989 for producing ingenol mebutate, its precursor ingenol, and related tiglian-3-one derivatives using Euphorbiaceae plant cell culture has been published by the World Intellectual Property Organization (WIPO). The patented method enables mass production of ingenol mebutate through suspension cell cultures, offering a potential alternative to existing commercial production methods for this secondary plant metabolite. The company intends to propose this Plant Cell Fermentation (PCF®) technology as a sustainable and scalable solution for manufacturing the drug ingredient, which is approved by both the FDA and EMA under the brand Picato® for topical treatment of actinic keratosis.PR NewswireDer Patentantrag von Phyton Biotech für eine neuartige Produktionsmethode von Ingenolmebutat wurde von der Weltorganisation für geistiges Eigentum (WIPO) veröffentlichtPhyton Biotech announced that its international patent application for a novel production method of ingenolmebutat via plant cell culture fermentation was published by the World Intellectual Property Organization (WIPO). This development represents a potential alternative for the scalable, commercial manufacturing of this difficult-to-produce molecule used in the drug Picato. The company aims to leverage this proprietary technology to provide sustainable and GMP-compliant supply solutions for complex plant-based active pharmaceutical ingredients.PR NewswireSolicitud de patente para un nuevo método de producción para el mebutato de ingenol en Phyton BiotechPhyton Biotech announced that its international PCT patent application (PCT/EP2016/055989) for a new method of producing ingenol mebutate through euphorbia plant cell culture has been published by the World Intellectual Property Organization (WIPO). The patent covers suspension cell cultures adapted for large-scale production of ingenol mebutate, offering a potential alternative for commercial-scale production of this difficult-to-manufacture molecule. The technology aims to provide sustainable and scalable GMP production of ingenol mebutate, its precursor ingenol, and other similar plant secondary metabolites.PR NewswirePatent Application Covering a Novel Production Method for Ingenol Mebutate at Phyton Biotech is Published by World Intellectual Property Organization (WIPO)Phyton Biotech announced the publication of its international patent application PCT/EP2016/055989 by the World Intellectual Property Organization, covering a novel production method for Ingenol Mebutate using Plant Cell Fermentation (PCF®) technology. The patented invention provides suspension cell cultures suitable for mass production of ingenol mebutate, offering a potential alternative for commercial scale production of this difficult-to-make molecule that is already approved by FDA and EMA under the brand Picato® for topical treatment of actinic keratosis. Phyton Biotech, headquartered in Germany with GMP facilities in Ahrensburg and Vancouver, Canada, aims to leverage this technology to enhance the value of its PCF® platform for sustainable and scalable GMP production of plant secondary metabolites.GlobeNewswirePatent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)GenSpera announced that its partner Phyton Biotech's patent application for producing thapsigargin via plant cell suspension culture was published by WIPO. The process offers a potential alternative to traditional plant cultivation for commercial-scale production. GenSpera's lead drug candidate mipsagargin, a thapsigargin prodrug, is in clinical trials for several tumor types.